DoD Rare Cancers, Idea Development Award
ID: 358794Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358794
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Rare Cancers Research Program (RCRP) Idea Development Award for fiscal year 2025. This grant aims to support innovative research that explores new ideas and develops impactful strategies in the area of rare cancers, which are defined as those affecting six or fewer individuals per 100,000 annually in the U.S. Eligible applicants include various organizations, and the program encourages interdisciplinary collaboration among military, academic, and industry sectors to enhance health outcomes for military Service Members, Veterans, and the broader public. The total estimated program funding is $6,860,000, with a funding limit of $490,000 per application. Key deadlines include a pre-application due by July 1, 2025, and a full application by October 6, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942525RCRPIDA_GG.pdf
    The Department of Defense's Defense Health Program has issued a funding opportunity for the Rare Cancers Research Program's (RCRP) Idea Development Award for fiscal year 2025, with a funding limit of $490,000 per application. The goal of this program is to support innovative research that explores new ideas and develops impactful strategies in the area of rare cancers, defined as those affecting six or fewer individuals per 100,000 annually in the U.S. Eligible applicants include various organizations, and each application undergoes a two-step submission process, starting with a pre-application due by July 1, 2025, and a full application by October 6, 2025. The review process involves peer and programmatic evaluations to ensure the projects' alignment with the program's mission. Key eligibility criteria emphasize the need for preliminary data and the potential impact of proposed research on rare cancer outcomes. The program encourages interdisciplinary collaboration among military, academic, and industry sectors, aiming to enhance the health outcomes of military Service Members, Veterans, and the broader public. Comprehensive submission requirements and review criteria outline a structured approach to applicant evaluation and project feasibility.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Staff Research Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity for the Staff Research Program, aimed at engaging scientific staff in collaborative research with higher education institutions. This program seeks to enhance the professional competence of Army Research Office (ARO) scientists through hands-on, fundamental research in various scientific fields, including engineering, physical sciences, and life sciences, with a focus on advancing knowledge relevant to Army missions. Eligible applicants include institutions recognized for their scientific research capabilities, and the funding will be provided through cooperative agreements with award amounts ranging from $200,000 to $10 million. Proposals must be submitted via Grants.gov by June 2, 2030, and interested parties can contact Mr. William Creech at William.a.creech3.civ@army.mil for further information.
    Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)," aimed at enhancing the training of a workforce to meet the nation’s biomedical and clinical research needs, particularly in cancer research. This program seeks applications that propose innovative educational activities, specifically hands-on cancer research experiences lasting 8 to 15 weeks, complemented by additional educational initiatives. With a funding ceiling of $300,000 per year for a project period of up to five years, the program encourages participation from underrepresented groups and aims to provide unique educational opportunities not covered by existing programs. Interested applicants can find more information and guidelines at the NIH website, with the application deadline set for January 25, 2026.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers, specifically for the fiscal years 2027, 2028, and 2029, under the P50 Clinical Trial Required grant program. This initiative aims to fund innovative translational research that enhances prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups, utilizing advanced cellular, molecular, and genetic approaches. With an estimated total program funding of $25 million and the expectation of awarding 12 grants, interested applicants must submit their proposals by January 25, 2027, with the anticipated award date set for June 4, 2027. For further inquiries, applicants can contact Bradley T. Scroggins at bradley.scroggins@nih.gov or by phone at 240-276-7860.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.